Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Eisai Launches Aricept Dry Syrup
June 26, 2013
- Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
- Success in Emerging Markets Key for Drug Makers’ Growth: IMS Japan Senior Principal
June 26, 2013
- Myelofibrosis Treatment Jakavi Reduced Risk of Death by 52% in 3-Year Follow-up Study: Novartis AG
June 26, 2013
- Anticancer Agent Xtandi Receives Approval Also in Europe: Astellas
June 26, 2013
- Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
- Novartis AG Probing 10-Plus Years of Documents, Emails over Diovan Papers
June 25, 2013
- Taiho to Launch New Formulation TS-1, World’s 1st Anticancer OD Tablets
June 25, 2013
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
- Kitasato Daiichi Sankyo Vaccine Submits NDA for Cell-Based Pandemic Flu Vaccine
June 24, 2013
- Industry FTC Finds Only 1 Violation of New Rules on Settai in FY2012 Following Their Introduction
June 21, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
- MSD Revives “US Training” Program to Enhance Skills of Outstanding MRs
June 21, 2013
- Baxter Receives Approval for Cell-Based H5N1 Vaccine
June 20, 2013
- Daiichi Sankyo Files NDA for Next Mainstay Product Prasugrel in Japan
June 20, 2013
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…